OVERVIEW / SUMMARY-Diabetes/Digital Health company simplifying blood glucose testing-POGO Automatic Monitor/Disposable Cartridge (FDA Cleared) (510k) (Rx/OTC)-Automatic blood collection with one-step testing for quick 4-second result-All-In-One 10 test cartridge without separate test strips/lancing device-Patterns app track/shares glucose data with healthcare providers-Coaching with diabetes educators to manage patient diabetesCAPITAL RAISED-Total capital raised $537 million (equity $404 million; debt $133 million)-$62 million round (September 2022) ($316 million valuation)-Filed S-1 for $75 million IPO (Goldman, Jefferies, Piper, Wells Fargo)REVENUE-Annualized revenue $8.8 million (growth from $588 thousand)SALES FORCE / CUSTOMERS-Reps 30+ Primary Care, Endocrinologists, Pharmacies, Retailers, PBM’s, Health Plans-Co-Promotion with Embecta for additional 25+ sales reps-Drug Wholesale Customers: AmerisourceBergen, Cardinal Health, McKesson-Pharmacy/Retail Customers: Costco, CVS, Kaiser, Kroger, Walgreens, Walmart-Employer Customers: eBen, Riverview Health, South University-Benefit Consultants: Aon/Hewitt, Mercer, National Business Group on Health, Willis Towers WatsonMARKET ACCESS / REIMBURSEMENT-3 largest PBM’s: CVS Caremark, Express Scripts, Optum + Kaiser (113+ million covered lives)-Co-Pay savings program with CoverMyMeds (McKesson)E-COMMERCE / DTC STORE-POGO Store on-line with mail order Rx Pharmacy (GEM Edwards)/OTC cash-Digital marketing with Bing, Facebook, Google, Instagram, Twitter FDA CLEARANCES (Rx/OTC) / CLINICAL TRIALS-Accuracy/precision trial on 285 people with diabetes (FDA Cleared) (510K)-Monitor with auto sampling/sample reapplication (FDA Cleared) (510k)-Monitor with color screen, Bluetooth and voice (FDA Cleared) (Special 510k)MANUFACTURING-Monitor manufactured by Foxconn (Mexico) (first medical product by Foxconn)-Cartridge manufactured in-house on high volume automated system (38 cartridges/minute)

OVERVIEW / SUMMARY-Women’s reproductive healthcare company-Fetal Fibronectin Test for preterm birth (FDA Approved) (Expedited PMA) -E‐tegrity Test for infertility (Adeza Diagnostic Services) (CLIA Certified Laboratory)-Gestiva, injectable therapeutic, to reduce risk of preterm birth (FDA Approved) (NDA)COMPANY SALE (April 2007)-$452 million all-cash (8.7 times revenue/227 times EBITDA)-Increased shareholder value 70% over IPO-6 offers to acquire company (3 medtech; 3 pharma) (sold to Cytyc/Hologic)IPO (December 2004)-$69 million IPO ($263+ million valuation) (priced at top of filing range)-Investor commitments of $740+ million/12 times oversubscribed-Investor close rate of 75+% into buy ordersREVENUE-Annualized revenue $62+ million (2007) (growth from $925 thousand)GROSS MARGINS / EBITDA-Product margins 92+%/pre‐tax income $9.3 million (2006)-19 consecutive quarters of profitability/positive cash flowCASH-Cash balance $100 million (2007)/$10 million cash generated (2006)SALES FORCE / CUSTOMERS-Direct sales force 95+ selling to Hospitals, Labs, HCP's, Health Plans-Co-Promotion with Abbott Nutrition (100+ Ob/Gyn reps)-Installed customer base 2,040+ hospitals/laboratoriesMARKET ACCESS / REIMBURSEMENT-20 largest US health plans + Kaiser (200+ million covered lives)FDA Approvals / Expedited Reviews / Clinical Trials-763 women with symptoms of preterm birth (FDA Approved) (PMA)-2,939 women without symptoms of preterm birth (FDA Approved) (PMA) -Rapid Fetal Fibronectin Test for preterm birth (FDA Approved) (Expedited PMA)GESTIVA (Injectable Therapeutic)-9 center double‐blind placebo-controlled trial (463 women)-Follow‐up study on 60+% of infants ages 2‐5-Filed 505(b)(2) new drug application (Approved by FDA Advisory Committee/FDA) (NDA)-Orphan drug designation by FDA (7 year market exclusivity)-Sold $675 million to AMAG Pharmaceuticals/Covis Pharma (2014) (vs $7M cost for FDA Approval)-Annualized revenue $180 million (2014)

OVERVIEW / SUMMARY-Co-Founder, Executive Vice President and Chief Operating Officer-Designed, Manufactured And Marketed Point‐Of‐Sale Credit Transaction SystemsCAPITAL RAISED-Raised $36 Million In Equity And $3 million In Debt-Equity Investors Included Capital Cities/ABC, Seiko Epson And The Hillman CompanyCUSTOMERS-Key Customers Included Arco AM/PM, Bakers Square, Kroger And Nathan’s COMPANY SALE -Sold To Leading VISA/MasterCard Credit Card Processing Company

OVERVIEW / SUMMARY-Designed, Manufactured And Marketed Video Game Systems/Software CartridgesMARKETING -Worldwide #2 Marketing Brand (Second Only To Coca-Cola)REVENUE / EBITDA-Revenue Growth Of $230 Million To $1.5 Billion / EBITDA Of $69 Million To $552 Million (3 Years)